Drug developers face unique challenges in pediatric rare disease trials, including small and geographically dispersed patient populations, strict ethical limits on sampling, and sparse early clinical data. In a competitive landscape where speed is critical and every month can influence funding rounds and regulatory milestones; traditional development approaches often fall short. However, forward-thinking strategies are transforming these challenges into […] The post Transforming Pediatric Rare D